Benzimidazole Derivatives As PI3 Kinase Inhibitors
    6.
    发明申请
    Benzimidazole Derivatives As PI3 Kinase Inhibitors 审中-公开
    苯并咪唑衍生物作为PI3激酶抑制剂

    公开(公告)号:US20130196990A1

    公开(公告)日:2013-08-01

    申请号:US13876853

    申请日:2011-09-23

    摘要: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

    摘要翻译: 本发明涉及苯并咪唑衍生物用于调节,特别是抑制磷酸肌醇3'OH激酶家族(以下称为PI3激酶),适当地PI3Kα,PI3Kdelta,PI3Kβ和/或PI3Kgamma的活性或功能的用途。 合适地,本发明涉及苯并咪唑在治疗一种或多种疾病状态中的用途,所述疾病状态选自:自身免疫性疾病,炎性疾病,心血管疾病,神经变性疾病,过敏,哮喘,胰腺炎,多器官衰竭,肾脏疾病,血小板聚集, 癌症,精子活力,移植排斥反应,移植物排斥反应和肺损伤。 更合适地,本发明涉及用于治疗癌症的PI3Kβ选择性苯并咪唑化合物。

    Pyrrolidine sulfonamides
    7.
    发明授权
    Pyrrolidine sulfonamides 失效
    吡咯烷磺酰胺

    公开(公告)号:US07019008B2

    公开(公告)日:2006-03-28

    申请号:US11119026

    申请日:2005-04-29

    IPC分类号: A61K31/496 C07D409/14

    CPC分类号: C07D409/12

    摘要: A compound of Formula (I): wherein: R1 is C1-6 alkyl, benzyl, or (CH2)n—C(O)NH2; wherein the benzyl may be unsubstituted or substituted by one or two C1-6 alkyl, halogen, C1-6 alkoxy, or methylenedioxy groups; R2 is benzimidazolyl, quinolinyl, benzofuranyl, napthyl, indolyl, benzothiophenyl, phenyl, furanyl, thienyl, or pyridyl substituted or unsubstituted by one, two or three halogen, C1-3 alkyl, C1-3 alkoxy, or methylenedioxy groups; X1 and X2 are independently hydrogen, halogen, C1-3 alkyl, C1-3 alkoxy, nitro, CF3, or CN; n is 1, 2, or 3; m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

    摘要翻译: 式(I)的化合物:其中:R 1是C 1-6烷基,苄基或(CH 2 CH 2) -C(O)NH 2; 其中苄基可以是未取代的或被一个或两个C 1-6烷基,卤素,C 1-6烷氧基或亚甲二氧基取代; R 2是苯并咪唑基,喹啉基,苯并呋喃基,萘基,吲哚基,苯并噻吩基,苯基,呋喃基,噻吩基或被1,2或3个卤素取代或未取代的吡啶基, 亚烷基,C 1-3烷氧基或亚甲二氧基; X 1和X 2独立地是氢,卤素,C 1-3烷基,C 1-3烷氧基 ,硝基,CF 3或CN; n为1,2或3; m为1,2或3; 或其药学上可接受的盐。